{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:48Z","timestamp":1793649168565,"version":"4.5.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LY21H300002"],"award-info":[{"award-number":["LY21H300002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073694"],"award-info":[{"award-number":["82073694"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474420"],"award-info":[{"award-number":["82474420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118170","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:38:18Z","timestamp":1758091098000},"page":"118170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis and bioactive evaluation of novel quinoline-linked sulfonamide-pyridine derivatives as PI3K\/HDAC dual-target inhibitors"],"prefix":"10.1016","volume":"301","author":[{"given":"Jinyu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-059X","authenticated-orcid":false,"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/eurpub\/ckz216","article-title":"Cancer statistics: a comparison between World health organization (WHO) and global burden of disease (GBD)","volume":"30","author":"Mattiuzzi","year":"2020","journal-title":"Eur. J. Publ. Health"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118170_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3322\/caac.21597","article-title":"Enhancing global access to cancer medicines","volume":"70","author":"Cortes","year":"2020","journal-title":"Ca-Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib3","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/acs.chemrev.3c00778","article-title":"Theranostic fluorescent Probes","volume":"124","author":"Sharma","year":"2024","journal-title":"Chem. Rev."},{"issue":"7782","key":"10.1016\/j.ejmech.2025.118170_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118170_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.cell.2017.11.035","article-title":"On the design of combination cancer therapy","volume":"171","author":"Doroshow","year":"2017","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118170_bib6","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118170_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118170_bib8","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus kinase (JAK) and histone deacetylase (HDAC) Bispecific inhibitors based on the moiety of Fedratinib for treatment of both Hematologic malignancies and solid cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118170_bib9","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118170_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118170_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem. Sci."},{"issue":"Pt 5","key":"10.1016\/j.ejmech.2025.118170_bib12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1242\/jcs.093773","article-title":"Classes of phosphoinositide 3-kinases at a glance","volume":"127","author":"Jean","year":"2014","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118170_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118170_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061571","article-title":"PI3K inhibitors for the treatment of chronic lymphocytic leukemia: Current status and future Perspectives","volume":"14","author":"Hus","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118170_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00300-X","article-title":"PI3K inhibitors in haematological malignancies","volume":"23","author":"Brown","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118170_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118170_bib19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/d41573-020-00190-1","article-title":"Targeted PI3K inhibitors reduce lung fibrosis in mice","volume":"19","author":"Cully","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase Ib study of Alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with Letrozole in ER+\/HER2- Metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118170_bib23","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The emerging role of PI3K inhibitors for solid tumour treatment and beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118170_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41571-021-00512-1","article-title":"Copanlisib safe and active in combination","volume":"18","author":"Killock","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118170_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118170_bib26","first-page":"243","volume":"212","author":"Zirlik","year":"2018"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118170_bib27","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2217\/fon-2018-0881","article-title":"Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia","volume":"15","author":"Frustaci","year":"2019","journal-title":"Future Oncol."},{"issue":"15","key":"10.1016\/j.ejmech.2025.118170_bib28","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory Indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib29","first-page":"342","article-title":"FDA approves PI3K inhibitor for a rare immune disorder","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118170_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2020.10.597","article-title":"The complex balance of PI3K inhibition","volume":"32","author":"Vanacker","year":"2021","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118170_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118170_bib32","article-title":"Discovery of a novel Benzimidazole derivative targeting histone deacetylase to induce Ferroptosis and trigger Immunogenic cell death","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2025.118170_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114049","article-title":"Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics","volume":"229","author":"Cui","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118170_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118170_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14728222.9.4.809","article-title":"Histone deacetylase inhibitors: insights into mechanisms of lethality","volume":"9","author":"Rosato","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118170_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41571-019-0224-2","article-title":"HDAC inhibitors tested in phase III trial","volume":"16","author":"Romero","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118170_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd4579","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"14","author":"Falkenberg","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118170_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/molecules27030715","article-title":"HDAC inhibitors: Innovative Strategies for their design and applications","volume":"27","author":"Da\u015bko","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drudis.2021.08.004","article-title":"Vorinostat in autophagic cell death: a critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention","volume":"27","author":"Patra","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"Supple 1","key":"10.1016\/j.ejmech.2025.118170_bib42","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1182\/blood-2022-159806","article-title":"Outcomes with Panobinostat in Heavily Pretreated multiple Myeloma patients","volume":"140","author":"Pan","year":"2022","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.ejmech.2025.118170_bib43","first-page":"3112","article-title":"Etctn P10500: phase 1 study of Tazemetostat Plus Belinostat for the treatment of relapsed or refractory lymphoma","volume":"144","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118170_bib44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41417-024-00760-0","article-title":"Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway","volume":"31","author":"Xia","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118170_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00432-024-05615-7","article-title":"Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K\/AKT\/mTOR pathway","volume":"150","author":"Wu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118170_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118170_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112648","article-title":"Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer","volume":"205","author":"Yao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118170_bib48","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-aminopyridine-based and 2-Aminopyrimidine-based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory solid tumors and hematological malignancies","author":"Saidahmatov","year":"2024","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2025.118170_bib49","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4155\/fmc-2019-0168","article-title":"Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors","volume":"11","author":"Liang","year":"2019","journal-title":"Future Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118170_bib50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-018-0788-2","article-title":"Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118170_bib51","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces Immunogenic Ferroptosis to potentiate cancer immune Checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118170_bib52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11523-023-01006-z","article-title":"Dual PI3K\/HDAC inhibitor BEBT-908 exhibits potent efficacy as Monotherapy for primary central Nervous system lymphoma","volume":"18","author":"Wang","year":"2023","journal-title":"Targeted Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118170_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118170_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115673","article-title":"A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118170_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114582","article-title":"Design, synthesis, and biological evaluation of bifunctional inhibitors against Hsp90-HDAC6 interplay","volume":"240","author":"Chae","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:33:09Z","timestamp":1773142389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"alternative-id":["S0223523425009353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118170","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioactive evaluation of novel quinoline-linked sulfonamide-pyridine derivatives as PI3K\/HDAC dual-target inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118170"}}